Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company known for its commitment to addressing ototoxicity in cancer patients undergoing cisplatin-based chemotherapy, is set to report its financial results for the full year and fourth quarter of 2025 on March 24, 2026. The announcement was made on March 18, 2026, indicating that results will be released prior to the U.S. market's opening. Following the financial release, Fennec’s management will host a conference call and webcast to discuss the implications and insights pertaining to their financial and business performance.

The conference call is scheduled for 8:30 a.m. Eastern Time on March 24, and interested parties can access the live webcast via a link provided on their official website. The webcast will also be archived for accessibility over the following thirty days, ensuring that stakeholders can review the discussion at their convenience.

Fennec Pharmaceuticals is particularly recognized for its product, PEDMARK®, which aims to mitigate the risk of platinum-induced ototoxicity. PEDMARK was granted FDA approval in September 2022, followed by European Commission approval in June 2023 and U.K. approval in October 2023 under the name PEDMARQSI. The company further expanded its reach by entering into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in multiple regions, including Europe and Australasia. The drug now has Orphan Drug Exclusivity in the U.S. and has also secured Pediatric Use Marketing Authorization in Europe, coupled with robust patent protections extending until 2039. For more updates, interested parties can visit the Fennec Pharmaceuticals website or follow its LinkedIn page.

As Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) approaches the release of its full year and fourth quarter 2025 financial results on March 24, 2026, investors should carefully analyze the potential impacts on stock performance and market sentiment. Given the company's focus on combating ototoxicity resulting from cisplatin chemotherapy through its product PEDMARK (PEDMARQSI in Europe), the upcoming earnings report is positioned as a crucial indicator of Fennec's market traction and financial stability.

Key aspects to monitor include sales performance for PEDMARK/PEDMARQSI, especially in light of its recent approvals and ongoing commercialization efforts. The exclusive licensing deal with Norgine Pharmaceuticals for the European market began in March 2024, and updates on sales figures could offer insight into the product's acceptance and market penetration. Investors should look for any commentary from management regarding their expectations of revenue growth, particularly with the product now commercially available in major markets like the U.K. and Germany.

Moreover, the recent Orphan Drug Exclusivity granted in the U.S. and the Pediatric Use Marketing Authorization in Europe provide important market advantages. However, potential investors should also consider the sustainability of growth, including pipeline developments or competitive factors in the evolving specialty pharmaceutical landscape.

During the upcoming conference call, it will be critical for management to articulate a clear strategy moving forward, especially regarding international expansion and operational efficiencies. With ongoing global pressures on healthcare spending, Fennec will need to demonstrate not only its commitment to innovative treatments but also its ability to achieve profitability.

In summary, while Fennec Pharmaceuticals presents a compelling case for investment driven by unmet medical needs, market participants should remain vigilant and attentive to the earnings call details for indications of future performance and strategic direction.